Ways to fit a PK model with some data below the quantification limit.
about
Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient dataHCV Kinetic Models and Their Implications in Drug DevelopmentPopulation pharmacokinetic analysis of panitumumab in patients with advanced solid tumorsDistinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic ModelingA pharmacokinetic evaluation and metabolite identification of the GHB receptor antagonist NCS-382 in mouse informs novel therapeutic strategies for the treatment of GHB intoxicationThe pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion.A Bayesian approach for PK/PD modeling with PD data below limit of quantification.Scale reduction of a systems coagulation model with an application to modeling pharmacokinetic-pharmacodynamic data.Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies.Comparison of models for analyzing two-group, cross-sectional data with a Gaussian outcome subject to a detection limit.New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections.Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.Tools to evaluate pharmacokinetics data for establishing maximum residue limits for approved veterinary drugs: examples from JECFA's work.The present and future of withdrawal period calculations for milk in the European Union: dealing with data below the limit of quantification.Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in CatsData Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo).Population Pharmacokinetic Model of Doxycycline Plasma Concentrations Using Pooled Study Data.Clinical outcomes and kinetics of propanil following acute self-poisoning: a prospective case series.Handling data below the limit of quantification in mixed effect models.Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data.Population pharmacokinetic modelling of rupatadine solution in 6-11 year olds and optimisation of the experimental design in younger children.Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children.Population pharmacokinetics of emtricitabine in HIV-1-infected adult patientsPopulation pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria.Missing data in model-based pharmacometric applications: points to consider.Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas.Estimating area under the curve and relative exposure in a pharmacokinetic study with data below quantification limit.Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIVBiopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin.Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. ColistinAttenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.Estimating transformations for repeated measures modeling of continuous bounded outcome data.Evaluation of different tests based on observations for external model evaluation of population analyses.A prospective observational study of the clinical toxicology of glyphosate-containing herbicides in adults with acute self-poisoning.Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models.Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjectsNon-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania.
P2860
Q26783646-C9FE34BF-5260-4373-8E3E-334B2A2F415DQ26801602-C5627380-8525-4D7D-B8C1-98FE2155F7B1Q28257098-77272798-CA8C-4B30-8139-472AE5052890Q28550711-5D858776-3CAE-4784-BF98-3C87565F4E60Q28821080-9C2E753F-CC54-4852-925B-95D70F2DEF7FQ30456107-9184C34F-24A1-4502-9039-E7BC334D4222Q30573792-1C4BFF20-5F81-4F0D-9839-685EA615E6F2Q30728857-8D063DEC-F195-4741-A26D-45369BC48EDCQ30790275-2321FE28-E829-4BB7-8C2E-91D35EB26ABAQ30815467-5D14D6A6-1CB7-4B37-9C95-793EA4C3D359Q30856181-CD5D4082-1DFA-46A8-820C-DC2AC71031C1Q30864336-941A2EB3-0776-44BB-9893-1EA7410BC8ACQ30919516-31B599CE-3640-471B-9EE7-BFCB1935AC3EQ30964404-D2905A6F-F253-422C-8FB6-C4AA5B816076Q31116477-250D8FC9-DCB9-4103-9265-28E4A03ADB1BQ31118795-B3326DCF-1557-47A4-8B75-1A80FEFEF6ECQ31138427-987A1C8F-2AF5-4610-B94A-1A74E2042B8AQ31147438-3732B971-47A3-4CDB-B3DE-E35F8102EAB3Q31152727-5527D92F-661A-4FFE-8DF3-83E00308814BQ33409751-F96FBF99-EA9F-4C97-8CAE-57D563740040Q33447430-FB201676-B84B-4F6C-B546-0C2ED6C6CCD7Q33521471-62348EA7-D527-40A0-BDE6-C221E3E8A461Q33574626-4493E7A2-DB38-4439-8060-3084F26AFB3BQ33601837-4D2248F4-5760-4772-B43B-84517799CC66Q33622825-97F55007-028F-4385-A923-DC891059693BQ33622892-C20C9A35-28C5-4363-B37D-5403C8170562Q33706156-1FFE1195-3D17-46BA-B6F3-D808562B7C60Q33729778-0D9A1BDD-7BAA-429B-B5FB-9355BEE60F1BQ33782019-336A0B53-930A-49DD-B294-7CF22CE57539Q33797999-D992550F-44D1-4F02-8E7F-8EA186D51241Q33798218-7112B227-3028-464E-A2DC-8F1A161F9DDFQ33798554-40870109-C86B-41D8-80A3-FFED67F74895Q33826267-25750BA9-E1FE-47EF-8A3A-E1FBE4C61167Q33864905-D1DAD659-BF5B-4B28-A496-58A9374D8B32Q33869167-7CD4BAD3-7206-41D3-AD3B-4819CEEE7E17Q33871583-45C18BA1-F0F3-4175-84CD-7685EDEB3E2FQ33917058-9BD49665-84E6-490F-9A8B-DAD037221EFDQ33998845-50F15BAB-B96B-4CCC-8557-DA4EF92FF3CCQ34037355-D139C308-54CE-4AF7-A24B-2AE440978EE2Q34058351-E675ED56-CD3B-4979-B0E7-3497449D7F2F
P2860
Ways to fit a PK model with some data below the quantification limit.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Ways to fit a PK model with some data below the quantification limit.
@ast
Ways to fit a PK model with some data below the quantification limit.
@en
type
label
Ways to fit a PK model with some data below the quantification limit.
@ast
Ways to fit a PK model with some data below the quantification limit.
@en
prefLabel
Ways to fit a PK model with some data below the quantification limit.
@ast
Ways to fit a PK model with some data below the quantification limit.
@en
P356
P1476
Ways to fit a PK model with some data below the quantification limit.
@en
P2093
P2888
P304
P356
10.1023/A:1012299115260
P577
2001-10-01T00:00:00Z
P6179
1050934479